share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/09/17 20:04

Moomoo AI 已提取核心訊息

Allarity Therapeutics announced that two patients in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have surpassed one year of treatment. These patients were pre-screened using Allarity's Drug Response Predictor (DRP®) companion diagnostic, which identified them as likely responders to the dual PARP/Tankyrase inhibitor treatment.The trial, conducted at multiple sites in the US and UK, implements a revised protocol with twice-daily dosing of stenoparib (200mg morning, 400mg evening). The enrolled patients, who had previously undergone multiple treatments including platinum, taxanes, and PARP inhibitors, demonstrated sustained clinical benefit with confirmed complete response and long-term disease stability.CEO Thomas Jensen emphasized the significance of extending life by 52 weeks in heavily pre-treated patients. The company is actively planning to accelerate stenoparib's path toward regulatory approval, with additional program updates expected in the coming months.
Allarity Therapeutics announced that two patients in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have surpassed one year of treatment. These patients were pre-screened using Allarity's Drug Response Predictor (DRP®) companion diagnostic, which identified them as likely responders to the dual PARP/Tankyrase inhibitor treatment.The trial, conducted at multiple sites in the US and UK, implements a revised protocol with twice-daily dosing of stenoparib (200mg morning, 400mg evening). The enrolled patients, who had previously undergone multiple treatments including platinum, taxanes, and PARP inhibitors, demonstrated sustained clinical benefit with confirmed complete response and long-term disease stability.CEO Thomas Jensen emphasized the significance of extending life by 52 weeks in heavily pre-treated patients. The company is actively planning to accelerate stenoparib's path toward regulatory approval, with additional program updates expected in the coming months.
Allarity Therapeutics宣佈，其針對晚期複發性卵巢癌的stenoparib二期臨牀試驗中有兩名患者的治療超過了一年。這些患者通過Allarity的藥物反應預測器（DRP®）伴隨診斷進行預先篩選，識別爲對雙PARP/Tankyrase抑制劑治療可能有反應者。該試驗在美國和英國的多個地點進行，實施了修訂的方案，每日兩次服用stenoparib（早晨200mg，晚上400mg）。註冊的患者之前已接受多種治療，包括鉑金、紫杉烯和PARP抑制劑，顯示出持續的臨牀益處，確認完全響應和長期疾病穩定。首席執行官托馬斯·延森強調，在重度預處理患者中延長生命52周的重要性。公司正積極計劃加速stenoparib的監管批准路徑，並預計在未來幾個月內提供更多項目更新。
Allarity Therapeutics宣佈，其針對晚期複發性卵巢癌的stenoparib二期臨牀試驗中有兩名患者的治療超過了一年。這些患者通過Allarity的藥物反應預測器（DRP®）伴隨診斷進行預先篩選，識別爲對雙PARP/Tankyrase抑制劑治療可能有反應者。該試驗在美國和英國的多個地點進行，實施了修訂的方案，每日兩次服用stenoparib（早晨200mg，晚上400mg）。註冊的患者之前已接受多種治療，包括鉑金、紫杉烯和PARP抑制劑，顯示出持續的臨牀益處，確認完全響應和長期疾病穩定。首席執行官托馬斯·延森強調，在重度預處理患者中延長生命52周的重要性。公司正積極計劃加速stenoparib的監管批准路徑，並預計在未來幾個月內提供更多項目更新。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。